KRAS and neoplasm: In patients with a wild-type KRAS tumour, the expression level of miR-181a showed a 1.87-fold increase in good responders compared to poor responders (p = 0.04), which was not observed in patients with mutated KRAS tumours (0.91-fold increase, p = 0.69).